Elisabeth Mocaer

TL;DR: Agomelatine (Valdoxan/Thymanax; Servier) was granted marketing authorization in 2009 for the treatment of major depression in Europe, thereby becoming the first approved antidepressant to incorporate a non-monoaminergic mechanism of action.

TL;DR: This study shows that an antidepressant can affect differentially various stages of neurogenesis in the dorsal and ventral hippocampus, which is consistent with the antidepressant-anxiolytic properties of the drug.

TL;DR: Its morning activity, which was not inhibited by a melatonin antagonist, indicates that these receptors are certainly required, but not sufficient to sustain the agomelatine efficacy, and it is suggested that the antidepressant-like activity of agomalatine depends on some combination of its melatonin agonist and 5-HT2C antagonist properties.

TL;DR: Results show that agomelatine treatment facilitates all stages of neurogenesis and suggest that a joint effect of melatonin agonism and 5HT2C antagonism may be involved in promotion by agomELatine of survival in the hippocampus.

TL;DR: The combined behavioral and electrochemical evidence supports the hypothesis that nAChR agonist-evoked cholinergic transients, which are characterized by rapid rise time and fast decay, predict robust drug-induced enhancement of attentional performance.